Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q4 2025
Jazz Pharmaceuticals (JAZZ) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the fourth quarter 2025 (Q4 2025), +10% from a year earlier and +6% from the quarter before. Operating margin was 21.2%, net earnings $203M (17.0% of revenue).
Jazz Pharmaceuticals, Q4 2025: revenue $1.2B (+10% year over year), operating margin 21.2%, net earnings $203M, operating cash flow $362M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +6% | +10% |
| Operating profit | $255M | +343% | +33% |
| Net earnings | $203M | -19% | +6% |
| Operating cash flow | $362M | -24% | -9% |
| Free cash flow | $346M | -25% | -10% |
What changed
Revenue was $1.2B in Q4 2025, up 10% year over year and up 6% from the previous quarter. Xywav was the largest line at 39% of revenue.
Operating profit was $0.25B, a 21.2% margin (up 3.7 points year over year). Of the extra revenue versus a year earlier, 58% reached operating profit, above the 18% margin then. Total costs grew 5% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+12%). Net earnings were $0.20B, up 6% year over year. The effective tax rate was 2.4%.
Operating cash flow was $0.36B (down 9% year over year), 178% of net earnings. Non-cash charges added back $0.18B of depreciation and amortization and $0.07B of share-based compensation. Working capital and other items used $0.09B. Capital expenditures of $0.02B left free cash flow of $0.35B.
Questions
What was Jazz Pharmaceuticals' revenue in the fourth quarter 2025?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the fourth quarter 2025 (Q4 2025), +10% from a year earlier and +6% from the quarter before.
Was Jazz Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $255M (21.2% of revenue) and net earnings $203M.